Memphasys (ASX:MEM) said the publication of a study in the "Antioxidants" journal reinforces the commercial potential as well as the scientific credibility of its RoXsta platform to identify oxidative stress in human and animal samples, according to a Thursday Australian bourse filing.
RoXsta is a proprietary antioxidant diagnostic platform for identifying oxidative stress-related deficiencies, and the study supports its ability to diagnose oxidative stress through analysis of biological fluids, the filing added.
The RoXsta system has potential for male infertility treatments as well as disease management in conditions such as neurodegenerative diseases, cardiovascular disorders, and cancer, the filing said.
It is also exploring its potential for the optimization of livestock productivity by mitigating oxidative stress.
Oxidative stress is linked to infertility, cardiovascular disease, neurodegenerative disorders, cancer, and other conditions, the filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.